ライフサイエンスコーパス: marginal donor

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 r exploration into the use of compromised or marginal donors.

2 y is of particular importance in organs from marginal donors.

3 t and therefore can no longer be regarded as marginal donors.

4 mber of ideal donors and greater reliance on marginal donors.

5 ould be cautiously considered as a source of marginal donors.

6 lture method to improve donor-organ use from marginal donors.

7 on graft survival, especially on grafts from marginal donors.

8 o assess the effects of EVNP in kidneys from marginal donors.

9 rding outcomes following use of grafts from "marginal" donors.

10 ions regarding the use of thyroid hormone in marginal donors are based on low-level evidence.

11 As such, kidneys from medically marginal donors are being considered for transplantation

12 s, could improve the quality of organs from "marginal" donors, broadening the criteria for donor acce

13 Kidney biopsies are being used to evaluate marginal donors, but rigorous statistical validation of

14 improve the quality of grafts from NHBD and marginal donors by abrogating the IRI insult.

15 Although marginal donor factors are recognized to influence clini

16 Recipients of marginal donor grafts did not have higher rates of compl

17 ra of organ shortage, the use of expanded or marginal donors has been attempted to increase transplan

18 ual-kidney transplantation using organs from marginal donors has been used at our center to expand th

19 Although these marginal donors have proved effective, there still remai

20 support continued aggressive utilization of marginal donor hearts in AL HT.

21 AHT) to investigate the possibility of using marginal donor hearts to expand the donor pool for cardi

22 Select marginal donor hearts used in AL HT do not have an incre

23 or improved clinical preservation of DCD and marginal donor hearts.

24 Ipsilateral placement of double kidneys from marginal donors into older recipients may reduce the str

25 Further use of marginal donors is limited by the requirement to assume

26 th no transplant (WLD); transplantation with marginal donor kidney (MDK); and "ideal" or optimal dono

27 LP) enables assessment and rehabilitation of marginal donor lungs before transplantation.

28 allows the evaluation and reconditioning of marginal donor lungs for use in transplantation.

29 neralization of current outcome data to more marginal donors not well represented in older studies.

30 ntation of kidneys from non-heart-beating or marginal donors or organs experiencing prolonged ischemi

31 zation over time by incentivizing the use of marginal donor organs and increasing access to transplan

32 hortage problem by reclaiming and preserving marginal donor organs including those from viable non-he

33 the potential to reclaim and preserve these marginal donor organs.

34 and furthermore improve the function of the marginal donor organs.

35 hich the use of Xe ex vivo could enhance the marginal donor pool of renal grafts by preventing graft

36 Exactly what constitutes a marginal donor remains ill defined.

37 d expand the donor pool, the use of certain "marginal donors," such as those who are hepatitis C viru

38 or pool, would allow surgeons to accept more marginal donors, thus potentially expanding the pool, wi

39 graft outcomes have been obtained with these marginal donor transplants, it is unclear whether recipi

40 The use of pancreatic grafts from marginal donors was analyzed for short-term and overall

41 ce using whole organ pancreatic grafts from "marginal" donors, which include grafts obtained from don

42 The use of organs from marginal donors who are hepatitis B surface antigen (HBs

43 to produce a scoring system to differentiate marginal donors with respect to risk of early allograft

44 In addition, using ultrasound to screen marginal donors would result in significant savings in m

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。